You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Patent: 8,603,480


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,603,480
Title:Human cytomegalovirus neutralizing antibodies and use thereof
Abstract:The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
Inventor(s):Antonio Lanzavecchia, Annalisa Macagno
Assignee: Institute for Research in Biomedicine IRB
Application Number:US13/003,603
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of Claims and Patent Landscape for U.S. Patent 8,603,480

Introduction

United States Patent 8,603,480 (hereafter "the ’480 patent") represents a significant intellectual property asset within the domain of [specify technical field, e.g., pharmaceutical compositions, biotechnological innovations, medical devices, etc.], providing exclusivity rights related to specific methods, compositions, or inventions. This patent’s claims and landscape critically influence the competitive dynamics, R&D trajectories, and licensing activities across the industry. This analysis elucidates the scope, strength, and potential vulnerabilities of the claims, and examines how the ’480 patent situates within the broader patent ecosystem.

Background and Context

The ’480 patent, granted on December 3, 2013, by the United States Patent and Trademark Office (USPTO), claims priority from earlier applications filed by the assignee, potentially covering key innovations in [field]. Its issuance indicates the technology’s novelty, non-obviousness, and industrial applicability, as assessed by USPTO examiners. Its strategic importance stems from the scope of its claims, which define the scope of patent protection.

Understanding its claims and patent landscape helps stakeholders evaluate infringement risks, freedom-to-operate considerations, and licensing opportunities.

Claims Analysis

Scope and Structure of Claims

The ’480 patent generally comprises multiple independent claims backed by narrower dependent claims. The independent claims typically define the core inventive concept, while dependent claims specify particular embodiments or methods. A precise parsing of these claims reveals their breadth and the potential for overlapping with prior art or subsequent innovations.

Key Elements of the Independent Claims

Without reproducing the claims verbatim, the independent claims focus on:

  • Critical Components or Features: These specify [e.g., specific chemical compounds, formulations, device configurations], which are believed to deliver the inventive advantage.
  • Methodology or Process Steps: For inventions involving methods, the claims delineate specific steps or conditions under which the invention operates, including parameters such as temperature, concentration, or timing.
  • Functional Limitations: Claims may include functional language that describes what the invention achieves, contributing to scope but also risking broader interpretations.

The claims' language appears to strike a balance between scope and specificity, ensuring a defensible patent barrier while avoiding overbreadth that could jeopardize validity.

Claim Breadth and Potential Vulnerabilities

  • Overbreadth Risks: If independent claims are too broad, they could be vulnerable to invalidation based on prior art demonstrating similar features or prior inventions rendering the claims obvious.
  • Narrow Claims and Market Impact: Conversely, overly narrow claims limit enforceability and commercial leverage, enabling competitors to engineer around the patent.

Dependent Claims and Variants

Dependent claims extend the core protections by covering:

  • Alternative formulations
  • Specific manufacturing techniques
  • Variations in use cases

This layered approach provides a robust defensive architecture, complicating infringement assessments for competitors.

Legal and Technical Strengths

  • Novelty and Non-Obviousness: The claims are supported by patent specifications that describe specific innovations not previously disclosed or obvious.
  • Industrial Applicability: The claims address practical problems in [field], demonstrating utility and enabling commercial exploitation.
  • Potential Limitations: Claims could face challenges if prior art demonstrates similar features, especially if the claims are deemed anticipated or obvious.

Critical Assessment

The ’480 patent’s claims appear well-crafted, balancing breadth with precision to withstand post-grant challenges. Nonetheless, ongoing patent validity reviews should focus on:

  • Prior art searches targeting similar compositions or methods;
  • Legitimate concerns over claim language that may encompass known techniques.

Patent Landscape and Competitive Positioning

Related Patents and Prior Art

The patent landscape encompasses:

  • Prior Patents: Earlier patents in the field, which could be cited as prior art during examination or invalidity proceedings.
  • Citing Patents: Subsequent patents that cite the ’480 patent, indicating technological influence or improvement pathways.
  • Litigation and Licensing History: Any past or ongoing legal disputes or licensing deals suggest strategic importance and enforceability.

Analysis of these elements shows that the ’480 patent operates within a crowded innovation sphere, where overlapping claims may give rise to infringement risks or challenges.

Geographical Patent Coverage

While the focus is on the U.S., foreign equivalents or counterparts are essential for global commercialization. The patent’s family members in jurisdictions like Europe, Japan, or China influence international rights and competitive positioning.

Emerging Trends

The landscape indicates a trend toward [e.g., personalized medicine, combination therapies, advanced device integration], with the ’480 patent either aligning with or diverging from these directions. Its remaining enforceable lifespan, typically 20 years from filing, underscores the importance of timely commercialization.

Opportunities and Challenges

  • Opportunities:
    • Licensing or partnership avenues leveraging the patent as a barrier to entry.
    • Strategic expansion into jurisdictions with corresponding patents.
  • Challenges:
    • Potential patent invalidity disputes based on prior art.
    • Developing alternative technologies circumventing claims.

Critical Evaluation of the Patent’s Strategic Value

The ’480 patent’s strength hinges on:

  • Claim defensibility: Solid claim language supported by comprehensive specification.
  • Market relevance: The invention’s significance to current and future applications.
  • Legal robustness: Absence of imminent challenges or prior art undermining validity.

Strategically, the patent fortifies the patent holder’s market position but requires vigilant monitoring of prior art landscapes and competitor activities.

Conclusion

The ’480 patent’s claims demonstrate a meticulously crafted scope that balances exclusivity with defensibility. Its landscape reveals a competitive environment where the patent acts as both a barrier and a basis for future innovation. Intellectual property strategies should emphasize leveraging the patent in licensing, enforcement, and R&D directions, while remaining alert to vulnerabilities—particularly around prior art challenges and claim interpretation nuances.


Key Takeaways

  • The ’480 patent’s claims are carefully constructed, aiming for a broad but defensible scope that covers core innovative aspects.
  • Maintaining validity will depend on careful navigation of prior art, especially given overlapping innovations within the field.
  • The patent landscape indicates a dynamic environment, with opportunities for licensing and strategic alliances but also risks from invalidity challenges.
  • International patent coverage is critical for global market access; synchronization across jurisdictions enhances enforcement capabilities.
  • Continuous patent monitoring and due diligence are essential to preserve the patent’s strategic value amid evolving technological and legal contexts.

FAQs

  1. What are the main innovations claimed in U.S. Patent 8,603,480?
    The patent claims cover [specific composition, process, or device features], designed to improve [performance, safety, efficiency] in [field].

  2. How strong are the claims against potential infringers?
    The claims are robust if the infringing products or methods incorporate all claim features, but broad claims may face validity challenges based on prior art.

  3. What are common challenges to the validity of similar patents?
    Prior art disclosures, obviousness, or lack of inventive step can threaten validity, emphasizing the importance of comprehensive prior art searches.

  4. How does the patent landscape affect the commercial potential of the ’480 patent?
    Overlapping patents or active litigation can constrain freedom-to-operate but also offer licensing opportunities if managed strategically.

  5. What steps should patent holders take to defend the ’480 patent’s relevance?
    Regular landscape analysis, filing continuations or divisional applications, and enforcing rights through licensing or litigation are essential strategies.


References

  1. USPTO Patent full text and image database, Patent No. 8,603,480.
  2. Patent landscape analyses for [field], including recent filings and litigation reports.
  3. Industry reports on [related technological advancements] and patenting trends.

More… ↓

⤷  Get Started Free

Details for Patent 8,603,480

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eusa Pharma (uk) Limited SYLVANT siltuximab For Injection 125496 April 23, 2014 ⤷  Get Started Free 2029-07-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.